tradingkey.logo
搜索

AxoGen Inc

AXGN
添加自选
44.020USD
-2.170-4.70%
收盘 07/01, 16:00美东报价延迟15分钟
2.08B总市值
亏损市盈率 TTM

关于 AxoGen Inc 公司

Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.

AxoGen Inc简介

公司代码AXGN
公司名称AxoGen Inc
上市日期Dec 17, 1986
CEODale (Michael Donald)
员工数量451
证券类型Ordinary Share
年结日Dec 17
公司地址13631 Progress Blvd.
城市ALACHUA
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编32615
电话13864626817
网址https://www.axogeninc.com/
公司代码AXGN
上市日期Dec 17, 1986
CEODale (Michael Donald)

AxoGen Inc公司高管

名称
名称/职务
职务
持股
持股变动
Ms. Lindsey Hartley
Ms. Lindsey Hartley
Chief Financial Officer
Chief Financial Officer
65.15K
+6.77%
Mr. Jens Schroeder Kemp
Mr. Jens Schroeder Kemp
Chief Marketing Officer
Chief Marketing Officer
64.95K
-6.16%
Mr. Paul G. Thomas
Mr. Paul G. Thomas
Independent Chairman of the Board
Independent Chairman of the Board
28.93K
+65.23%
Mr. Erick Wayne Devinney
Mr. Erick Wayne Devinney
Chief Innovation Officer
Chief Innovation Officer
--
--
Ms. Amy A. Mcbride-Wendell
Ms. Amy A. Mcbride-Wendell
Lead Independent Director
Lead Independent Director
--
--
Mr. Alan M. Levine
Mr. Alan M. Levine
Independent Director
Independent Director
--
--
Mr. John H. Johnson
Mr. John H. Johnson
Independent Director
Independent Director
--
--
Mr. William P. (Bill) Burke
Mr. William P. (Bill) Burke
Independent Director
Independent Director
--
--
Dr. Joseph (Adrian) Tyndall, M.D.
Dr. Joseph (Adrian) Tyndall, M.D.
Independent Director
Independent Director
--
--
Mr. Marc A. Began
Mr. Marc A. Began
Executive Vice President, Chief Compliance Officer, General Counsel
Executive Vice President, Chief Compliance Officer, General Counsel
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Lindsey Hartley
Ms. Lindsey Hartley
Chief Financial Officer
Chief Financial Officer
65.15K
+6.77%
Mr. Jens Schroeder Kemp
Mr. Jens Schroeder Kemp
Chief Marketing Officer
Chief Marketing Officer
64.95K
-6.16%
Mr. Paul G. Thomas
Mr. Paul G. Thomas
Independent Chairman of the Board
Independent Chairman of the Board
28.93K
+65.23%
Mr. Erick Wayne Devinney
Mr. Erick Wayne Devinney
Chief Innovation Officer
Chief Innovation Officer
--
--
Ms. Amy A. Mcbride-Wendell
Ms. Amy A. Mcbride-Wendell
Lead Independent Director
Lead Independent Director
--
--
Mr. Alan M. Levine
Mr. Alan M. Levine
Independent Director
Independent Director
--
--

常见问题

AxoGen Inc的前五大股东是谁?

AxoGen Inc 的前五大股东如下:Ms. Lindsey Hartley

有多少机构持有AxoGen Inc(AXGN)的股份?

截至2026Q1,共有399家机构持有AxoGen Inc的股份,合计持有的股份价值约为48.71M,占公司总股份的91.60%。与2025Q4相比,机构持股有所增加,增幅为3148593.00。